COGNITION THERAPEUTICS INC 8K

Cognition Therapeutics reported Q2 2026 financial results, extended its cash runway into Q4 2027, and announced clinical, regulatory, and IP advances for its lead candidate zervimesine, including movement toward a Phase 3 DLB psychosis trial and a patent expected to extend protection to 2045.

On August 6, 2026, Cognition Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a business update, highlighting progress toward a planned Phase 3 trial of lead candidate zervimesine (CT1812) in dementia with Lewy bodies psychosis following an FDA meeting on registrational trial design, receipt of a Notice of Allowance for a new composition-of-matter patent expected to extend IP protection for zervimesine to 2045, extension of a zervimesine expanded access program in DLB through 2027 with additional philanthropic funding, and presentation of a proposed Phase 3 study design at AAIC, while disclosing quarter-end cash and grants totaling roughly $56.4 million, an estimated cash runway into Q4 2027, a significant year-over-year reduction in R&D expenses, and a narrowed net loss of $3.9 million for the quarter.

Filing Facts

CIK

1455365

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-092037

Alert Tier

6